JPH07121942B2 - ５−ヘテロイルインドール誘導体 - Google Patents

５−ヘテロイルインドール誘導体

Info

Publication number
JPH07121942B2
JPH07121942B2 JP4505422A JP50542292A JPH07121942B2 JP H07121942 B2 JPH07121942 B2 JP H07121942B2 JP 4505422 A JP4505422 A JP 4505422A JP 50542292 A JP50542292 A JP 50542292A JP H07121942 B2 JPH07121942 B2 JP H07121942B2
Authority
JP
Japan
Prior art keywords
indol
mmol
thiazole
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP4505422A
Other languages
English (en)
Japanese (ja)
Other versions
JPH06500122A (ja
Inventor
ノワコウスキー，ジヨランタ・テレサ
Original Assignee
フアイザー・インコーポレイテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フアイザー・インコーポレイテツド filed Critical フアイザー・インコーポレイテツド
Publication of JPH06500122A publication Critical patent/JPH06500122A/ja
Publication of JPH07121942B2 publication Critical patent/JPH07121942B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Luminescent Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
JP4505422A 1991-02-12 1992-02-03 ５−ヘテロイルインドール誘導体 Expired - Lifetime JPH07121942B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65471291A 1991-02-12 1991-02-12
US654,712 1991-02-12

Publications (2)

Publication Number Publication Date
JPH06500122A JPH06500122A (ja) 1994-01-06
JPH07121942B2 true JPH07121942B2 (ja) 1995-12-25

Family

ID=24625959

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4505422A Expired - Lifetime JPH07121942B2 (ja) 1991-02-12 1992-02-03 ５−ヘテロイルインドール誘導体

Country Status (24)

Country Link
EP (1) EP0571471B1 (enExample)
JP (1) JPH07121942B2 (enExample)
KR (1) KR930703305A (enExample)
AT (1) ATE135005T1 (enExample)
AU (1) AU655456B2 (enExample)
CA (1) CA2101521A1 (enExample)
CZ (1) CZ165693A3 (enExample)
DE (1) DE69208868T2 (enExample)
DK (1) DK0571471T3 (enExample)
ES (1) ES2084347T3 (enExample)
FI (1) FI933551L (enExample)
GR (1) GR3019778T3 (enExample)
HU (1) HUT65766A (enExample)
IE (1) IE920442A1 (enExample)
IL (1) IL100888A0 (enExample)
MX (1) MX9200569A (enExample)
MY (1) MY131298A (enExample)
NO (1) NO932859D0 (enExample)
NZ (1) NZ241584A (enExample)
PT (1) PT100114A (enExample)
TW (1) TW263508B (enExample)
WO (1) WO1992013856A1 (enExample)
YU (1) YU13792A (enExample)
ZA (1) ZA92969B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW288010B (enExample) * 1992-03-05 1996-10-11 Pfizer
RU2101283C1 (ru) * 1992-04-07 1998-01-10 Пфайзер Инк. Производные индола или их фармацевтически приемлемые соли
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
GB9226532D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
GB9226537D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
ES2070087B1 (es) * 1993-08-13 1996-02-16 Pfizer Derivados de indol
US6423731B2 (en) 1994-01-06 2002-07-23 Zeneca Limited Indole derivatives as prodrugs of 5-HT1-like receptor agonists
US5468768A (en) * 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antimigraine derivatives of indolylcycloalkanylamines
EP0759918A1 (en) * 1994-05-19 1997-03-05 MERCK SHARP & DOHME LTD. Piperazine, piperidine and tetrahydropyridine derivatives of indol-3-ylalkyl as 5-ht1d-alpha agonists
PT765322E (pt) * 1994-06-01 2002-01-30 Astrazeneca Ab Derivados indole pro-farmacos de agonistas de receptores tipo 5-ht1
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
GB9501865D0 (en) * 1995-01-31 1995-03-22 Merck Sharp & Dohme Therapeutic agents
CN1184425A (zh) * 1995-03-20 1998-06-10 伊莱利利公司 5－取代－3－(1,2,3,6－四氢吡啶－4－基)－和3－(哌啶－4－基)－1h－吲哚:新型5－ht1f激动剂
JPH11513666A (ja) * 1995-10-10 1999-11-24 イーライ・リリー・アンド・カンパニー Ｎ−［２−置換−３−（２−アミノエチル）−１ｈ−インドール−５−イル］−アミド：新規５−ｈｔ▲下１ｆ▼作動剤
GB9523583D0 (en) * 1995-11-17 1996-01-17 Merck Sharp & Dohme Therapeutic agents
FR2754709B1 (fr) 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
FR2763243A1 (fr) * 1997-05-14 1998-11-20 Pf Medicament Utilisation d'amines indoliques comme medicaments antithrombotiques
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
ATE241615T1 (de) * 1998-03-09 2003-06-15 Lundbeck & Co As H 5-heteroaryl-substituierte indole
WO2000000487A1 (en) * 1998-06-30 2000-01-06 Eli Lilly And Company 5-ht1f agonists
ATE375990T1 (de) * 1999-04-21 2007-11-15 Nps Allelix Corp Piperidin-indol derivate mit 5-ht6 affinität
WO2001034146A1 (en) * 1999-11-08 2001-05-17 Smithkline Beecham Corporation Novel anti-infectives
KR100823908B1 (ko) 2000-10-20 2008-04-21 바이오비트럼 에이비(피유비엘) 2-, 3-, 4-, 또는 5-치환-ｎ1-(벤젠술포닐)인돌 및 이의치료 용도
DE10121217A1 (de) * 2001-04-30 2002-10-31 Merck Patent Gmbh 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden
WO2003099206A2 (en) 2002-05-21 2003-12-04 Bristol-Myers Squibb Company Indole compounds useful as impdh inhibitors
EP1581492B1 (en) 2002-11-28 2008-07-16 Suven Life Sciences Limited N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
WO2005005439A1 (en) * 2003-07-09 2005-01-20 Suven Life Sciences Limited Benzothiazino indoles
US20050245540A1 (en) * 2003-12-09 2005-11-03 Fujisawa Pharmaceutical Co., Ltd. New methods
WO2005121132A1 (ja) * 2004-06-11 2005-12-22 Shionogi & Co., Ltd. 抗ｈｃｖ作用を有する縮合ヘテロ環化合物
JP5833804B2 (ja) 2005-04-13 2015-12-16 ニューラクソン，インコーポレーテッド Ｎｏｓ阻害活性を有する置換インドール化合物
KR20080031038A (ko) * 2005-07-29 2008-04-07 4에스체 악티엔게젤샤프트 신규의 헤테로환 ＮＦ-κＢ 억제제
AU2007217040A1 (en) 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-HT6 receptor affinity
TW200808780A (en) 2006-04-13 2008-02-16 Neuraxon Inc 1,5 and 3,6- substituted indole compounds having NOS inhibitory activity
EP2049481A2 (en) * 2006-08-09 2009-04-22 SmithKline Beecham Corporation Novel compounds as antagonists or inverse agonists for opioid receptors
TW200848021A (en) 2007-03-06 2008-12-16 Wyeth Corp Sulfonylated heterocycles useful for modulation of the progesterone receptor
MX356032B (es) 2007-11-16 2018-04-11 Neuraxon Inc Compuestos indola y métodos para tratar el dolor visceral.
JP6063870B2 (ja) * 2010-11-08 2017-01-18 ライセラ・コーポレイション ＲＯＲγ活性の阻害用のＮ−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療
RU2014149136A (ru) 2012-05-08 2016-07-10 Мерк Шарп И Доум Корп. ТЕТРАГИДРОНАФТИРИДИНОВЫЕ И РОДСТВЕННЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ RORγ АКТИВНОСТИ И ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ
WO2013169864A2 (en) 2012-05-08 2013-11-14 Lycera Corporation TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
US9783511B2 (en) 2013-12-20 2017-10-10 Lycera Corporation Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
US9663502B2 (en) 2013-12-20 2017-05-30 Lycera Corporation 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
US9809561B2 (en) 2013-12-20 2017-11-07 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
MX2016010998A (es) 2014-02-27 2017-03-31 Lycera Corp Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados.
JP6523337B2 (ja) 2014-05-05 2019-05-29 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
US9896441B2 (en) 2014-05-05 2018-02-20 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
CA2975997A1 (en) 2015-02-11 2016-08-18 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as rorgammat inhibitors and uses thereof
CA2982847A1 (en) 2015-05-05 2016-11-10 Lycera Corporation Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
HK1253734A1 (zh) 2015-06-11 2019-06-28 The Regents Of The University Of Michigan 用作RORγ激动剂和用於治疗疾病的芳基二氢-2H-苯并[B][1，4]恶嗪磺酰胺和相关化合物
CA3002850A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Substituted indazole compounds as rorgammat inhibitors and uses thereof
AU2016344111A1 (en) 2015-10-27 2018-05-10 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
JP2018531958A (ja) 2015-10-27 2018-11-01 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγＴ阻害薬としてのヘテロアリール置換安息香酸及びその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8332437D0 (en) * 1983-12-06 1984-01-11 Glaxo Group Ltd Chemical compounds
DE3678805D1 (de) * 1985-11-08 1991-05-23 Glaxo Group Ltd Indolderivate.
GB8600398D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
SI9111010B (sl) * 1990-06-07 2005-02-28 Astrazeneca Ab 3,5-disubstituirani indolni derivati kot "5-HT1-podobni" receptorski agonisti

Also Published As

Publication number Publication date
IL100888A0 (en) 1992-11-15
EP0571471B1 (en) 1996-03-06
IE920442A1 (en) 1992-08-12
GR3019778T3 (en) 1996-07-31
ZA92969B (en) 1993-08-11
YU13792A (sh) 1994-11-15
HU9302328D0 (en) 1993-10-28
DE69208868T2 (de) 1996-10-17
ES2084347T3 (es) 1996-05-01
FI933551A0 (fi) 1993-08-11
HUT65766A (en) 1994-07-28
WO1992013856A1 (en) 1992-08-20
JPH06500122A (ja) 1994-01-06
MY131298A (en) 2007-08-30
FI933551A7 (fi) 1993-08-11
AU655456B2 (en) 1994-12-22
NZ241584A (en) 1994-12-22
DK0571471T3 (da) 1996-04-01
KR930703305A (ko) 1993-11-29
AU1263792A (en) 1992-09-07
DE69208868D1 (de) 1996-04-11
NO932859L (no) 1993-08-11
TW263508B (enExample) 1995-11-21
MX9200569A (es) 1992-08-01
NO932859D0 (no) 1993-08-11
CZ165693A3 (en) 1994-05-18
FI933551L (fi) 1993-08-11
PT100114A (pt) 1993-05-31
CA2101521A1 (en) 1992-08-13
ATE135005T1 (de) 1996-03-15
EP0571471A1 (en) 1993-12-01

Similar Documents

Publication Publication Date Title
JPH07121942B2 (ja) ５−ヘテロイルインドール誘導体
US5409941A (en) 5-heteroyl indole derivatives
JP2786480B2 (ja) １―インドリルアルキル―４―（置換ピリジニル）ピペラジン
JP2722279B2 (ja) アミノメチレンで置換した非芳香族複素環式化合物及びサブスタンスｐのアンタゴニストとしての使用
JP2505875B2 (ja) アザ環状置換基結合の５員環系
CN1281608C (zh) 新氮杂－吲哚基衍生物
CN1165537C (zh) 作为5-ht2c兴奋剂的吡咯并吲哚、吡啶并吲哚和氮杂�并吲哚
WO1993014084A2 (en) Piperidine derivatives
US4458076A (en) 3-(4-Piperidinyl)-1,2-benzisothiazoles
US5717102A (en) Indole derivatives as 5-HT1 agonists
SK50895A3 (en) 3-indolylpiperidine derivative, method of its preparation, its use for preparation of pharmaceutical composition and pharmaceutical composition containing them
EP0337767B1 (en) Cyclic amides
US5330986A (en) Indole-7-carboxamide derivatives
JPH09500611A (ja) 新規ピペリジニルチオインドール誘導体、それらの調製方法および、特に鎮痛剤として有用な、それらを含有する医薬組成物
US5510359A (en) Heteroaromatic 5-hydroxytryptamine receptor agonists
JP2006506346A (ja) ｐ３８キナーゼ阻害剤としてのインドール系誘導体
WO2002014277A1 (en) Biphenylcarboxamidoisoindoline compounds, processes for the preparation of the same and intermediates for the synthesis thereof
US6057340A (en) Oxazole derivatives as serotonin-1A receptor agonists
CN1349520A (zh) 用作5－羟色胺能药物的新型二唑衍生物
JPH11209344A (ja) 含窒素複素環化合物
CN1219173A (zh) 吡咯并吖庚因化合物
US5047402A (en) Cyclic amides as medicaments
JPWO1997003964A1 (ja) インドール誘導体
HK1019443A1 (en) Substituted indazole derivatives and their use as inhibitors phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
HK1019443B (en) Substituted indazole derivatives and their use as inhibitors phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)